The catalytic inhibitors of the immunoregulatory enzyme indoleamine 2,3-dioxygenase 1 (IDO1) are investigational drugs for cancer that have been developed with the rationale of reinvigorating the immune responses against the tumor. This evidence concerns the gene IDO1 and neoplasm.